Literature DB >> 14742204

Pharmacokinetics of total and unbound ertapenem in healthy elderly subjects.

D G Musson1, A Majumdar, S Holland, K Birk, L Xi, G Mistry, D Sciberras, J Muckow, P Deutsch, J D Rogers.   

Abstract

Ertapenem is a new once-a-day parenteral carbapenem antimicrobial agent. The pharmacokinetics of unbound and total concentrations of ertapenem in plasma were investigated in elderly subjects and compared with historical data from young adults. In a single- and multiple-dose study, healthy elderly males and females (n = 14) 65 years old or older were given a 1-g intravenous (i.v.) dose once daily for 7 days. Plasma and urine samples collected for 24 h on days 1 and 7 following administration of the 1-g doses were analyzed by reversed-phase high-performance liquid chromatography. Areas under the concentration-time curve from 0 h to infinity (AUC(0- infinity )) for elderly females and males were similar following administration of 1-g single i.v. doses, and thus, the genders were pooled in subsequent analyses. Concentrations in plasma and the half-life of ertapenem were generally higher and longer, respectively, in elderly subjects than in young adults. The mean AUC(0- infinity ) of total ertapenem in the elderly was 39% higher than that in young subjects following administration of a 1-g dose. The differences were slightly greater for the mean AUC(0- infinity ) of unbound ertapenem (71%). The unbound fraction of ertapenem in elderly subjects ( approximately 5 to 11%) was generally greater than that in young adults ( approximately 5 to 8%). As in young adults, ertapenem did not accumulate upon multiple dosing in the elderly. The pharmacokinetics of ertapenem in elderly subjects, while slightly different from those in young adults, do not require a dosage adjustment for elderly patients.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14742204      PMCID: PMC321530          DOI: 10.1128/AAC.48.2.521-524.2004

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  7 in total

1.  In vitro activity of ertapenem against common clinical isolates in relation to human pharmacokinetics.

Authors:  I Friedland; L A Mixson; A Majumdar; M Motyl; G L Woods
Journal:  J Chemother       Date:  2002-10       Impact factor: 1.714

2.  High-performance liquid chromatographic methods for the determination of a new carbapenem antibiotic, L-749,345, in human plasma and urine.

Authors:  D G Musson; K L Birk; A M Cairns; A K Majumdar; J D Rogers
Journal:  J Chromatogr B Biomed Sci Appl       Date:  1998-12-11

3.  Age and ceftriaxone kinetics.

Authors:  J R Luderer; I H Patel; J Durkin; D W Schneck
Journal:  Clin Pharmacol Ther       Date:  1984-01       Impact factor: 6.875

4.  Pharmacokinetics of ertapenem in healthy young volunteers.

Authors:  A K Majumdar; D G Musson; K L Birk; C J Kitchen; S Holland; J McCrea; G Mistry; M Hesney; L Xi; S X Li; R Haesen; R A Blum; R L Lins; H Greenberg; S Waldman; P Deutsch; J D Rogers
Journal:  Antimicrob Agents Chemother       Date:  2002-11       Impact factor: 5.191

5.  Assay methodology for the quantitation of unbound ertapenem, a new carbapenem antibiotic, in human plasma.

Authors:  Donald G Musson; Kimberly L Birk; Chester J Kitchen; Jin Zhang; John Y K Hsieh; Wei Fang; Anup K Majumdar; John D Rogers
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2003-01-05       Impact factor: 3.205

6.  Dose-dependent plasma clearance of MK-826, a carbapenem antibiotic, arising from concentration-dependent plasma protein binding in rats and monkeys.

Authors:  B K Wong; P J Bruhin; J H Lin
Journal:  J Pharm Sci       Date:  1999-02       Impact factor: 3.534

Review 7.  Clinical pharmacokinetic considerations in the elderly. An update.

Authors:  S Dawling; P Crome
Journal:  Clin Pharmacokinet       Date:  1989-10       Impact factor: 6.447

  7 in total
  10 in total

1.  Pharmacokinetics of ertapenem following intravenous and subcutaneous infusions in patients.

Authors:  Denis Frasca; Sandrine Marchand; Franck Petitpas; Claire Dahyot-Fizelier; William Couet; Olivier Mimoz
Journal:  Antimicrob Agents Chemother       Date:  2009-11-23       Impact factor: 5.191

2.  In vitro and in vivo assessment of linezolid combined with ertapenem: a highly synergistic combination against methicillin-resistant Staphylococcus aureus.

Authors:  Cedric Jacqueline; Jocelyne Caillon; Olivier Grossi; Virginie Le Mabecque; Anne-Françoise Miegeville; Denis Bugnon; Eric Batard; Gilles Potel
Journal:  Antimicrob Agents Chemother       Date:  2006-07       Impact factor: 5.191

3.  Carbapenem-Containing Combination Antibiotic Therapy against Carbapenem-Resistant Uropathogenic Enterobacteriaceae.

Authors:  Maria Loose; Isabell Link; Kurt G Naber; Florian M E Wagenlehner
Journal:  Antimicrob Agents Chemother       Date:  2019-12-20       Impact factor: 5.191

Review 4.  Use of pharmacodynamic principles to optimise dosage regimens for antibacterial agents in the elderly.

Authors:  Ayman M Noreddin; Virginia Haynes
Journal:  Drugs Aging       Date:  2007       Impact factor: 3.923

Review 5.  Ertapenem: a review of its use in the treatment of bacterial infections.

Authors:  Gillian M Keating; Caroline M Perry
Journal:  Drugs       Date:  2005       Impact factor: 9.546

6.  Pharmacokinetics of ertapenem in critically ill patients receiving continuous venovenous hemodialysis or hemodiafiltration.

Authors:  Rachel F Eyler; A Mary Vilay; Ahmed M Nader; Michael Heung; Melissa Pleva; Kevin M Sowinski; Daryl D DePestel; Fritz Sörgel; Martina Kinzig; Bruce A Mueller
Journal:  Antimicrob Agents Chemother       Date:  2013-12-09       Impact factor: 5.191

7.  Bactericidal activities of meropenem and ertapenem against extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in a neutropenic mouse thigh model.

Authors:  C Andrew DeRyke; Mary Anne Banevicius; Hong Wei Fan; David P Nicolau
Journal:  Antimicrob Agents Chemother       Date:  2007-02-05       Impact factor: 5.191

8.  Pharmacokinetics of Ertapenem in Sheep (Ovis aries) with Experimentally Induced Urinary Tract Infection.

Authors:  Joe S Smith; David J Borts; Clare C Slagel; Suzanne M Rajewski; Alain Bousquet-Melou; Aude A Ferran; Paul J Plummer; Jon P Mochel
Journal:  Comp Med       Date:  2019-10-03       Impact factor: 0.982

9.  Model-Informed Drug Development, Pharmacokinetic/Pharmacodynamic Cutoff Value Determination, and Antibacterial Efficacy of Benapenem against Enterobacteriaceae.

Authors:  Xi-Wei Ji; Feng Xue; Zi-Sheng Kang; Wei Zhong; Isabelle Hui-San Kuan; Xi-Ping Yang; Xiao Zhu; Yun Li; Yuan Lv
Journal:  Antimicrob Agents Chemother       Date:  2020-02-21       Impact factor: 5.191

10.  Mechanical plus oral bowel preparation with paromomycin and metronidazole reduces infectious complications in elective colorectal surgery: a matched case-control study.

Authors:  Matthias Mehdorn; Christoph Lübbert; Iris F Chaberny; Ines Gockel; Boris Jansen-Winkeln
Journal:  Int J Colorectal Dis       Date:  2021-04-25       Impact factor: 2.571

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.